{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T14:42:14Z","timestamp":1714228934068},"reference-count":13,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10921,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1982,9]]},"abstract":"<jats:p>The potential influence of the selective beta 2\u2010adrenoceptor agonist terbutaline on the serum concentration of the thyroid hormones in humans was studied in 11 healthy euthyroid subjects. Five served as a control group without medication while six received 5 mg terbutaline three times daily for 2 weeks. No significant differences were found between the two groups by measuring the serum concentrations of thyroxine, triiodothyronine, reverse triiodothyronine and resin\u2010 triiodothyronine uptake. The use of a beta 2\u2010adrenergic receptor stimulating drug is relatively contraindicated in untreated thyrotoxicosis. This recommendation is based upon a summation of clinical adverse reactions and not due to an effect on the serum concentrations of thyroid hormones.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1982.tb02006.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T16:58:23Z","timestamp":1343321903000},"page":"447-448","source":"Crossref","is-referenced-by-count":0,"title":["Beta 2\u2010adrenoceptor agonists and thyroid hormones."],"prefix":"10.1111","volume":"14","author":[{"given":"JP","family":"Kampmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TL","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Skovsted","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molholm JE","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(77)90025-2"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0450163"},{"key":"e_1_2_1_4_1","first-page":"184","article-title":"Beta\u2010blockers in thyrotoxicosis.","author":"MERCK","year":"1980","journal-title":"Lancet"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.281.6232.24"},{"key":"e_1_2_1_6_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.0954-6820.1979.tb00714.x","article-title":"The effect of suppressive therapy of non\u2010toxic diffuse goitre on serum levels of thyroxine, 3, 5, 3\u2032\u2010triiodothyronine and 3, 5\u2032, 5\u2032\u2010triiodothyronine","volume":"624","author":"JOHANSEN K.","year":"1979","journal-title":"Acta med. Scand."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1977.tb03322.x"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/endo-97-2-332"},{"key":"e_1_2_1_9_1","doi-asserted-by":"crossref","unstructured":"PERRILD H. M\u00d8LHOLM HANSEN J. SKOVSTED L.&CHRISTENSEN KORSGAARD L.(1982).Different effects of propranolol alprenolol sotalol atenolol and metoprolol on serum T3and rT3in hyperthyroidism. Submitted for publication.","DOI":"10.1111\/j.1365-2265.1983.tb03196.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb05844.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(72)90133-9"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91532-X"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-41-3-485"},{"key":"e_1_2_1_14_1","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/S0021-9258(17)40528-X","article-title":"Thyroid hormone regulation of beta2\u2010adrenergic receptor number.","volume":"252","author":"WILLLAMS L.","year":"1977","journal-title":"J. biol. Chem."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1982.tb02006.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1982.tb02006.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T14:18:20Z","timestamp":1714227500000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1982.tb02006.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1982,9]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1982,9]]}},"alternative-id":["10.1111\/j.1365-2125.1982.tb02006.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1982.tb02006.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1982,9]]}}}